发布: 2026年04月05日第16卷第7期 DOI: 10.21769/BioProtoc.5661 浏览次数: 367
评审: Sébastien GillotinSam PatelAnu Thomas

相关实验方案

采用 Davidson 固定液和黑色素漂白法优化小鼠眼组织切片的免疫组化染色
Anne Nathalie Longakit [...] Catherine D. Van Raamsdonk
2025年11月20日 1971 阅读
Abstract
Patient-derived glioblastoma (GBM) cells are valuable models for GBM research due to their rarity and the highly lethal nature of this cancer. Preserving these cells through long-term cryopreservation is therefore essential for advancing future investigations. However, recent studies have reported that standard cell recovery protocols are inefficient, resulting in poor cell survival and limited regrowth. Here, we established an optimized culture protocol that enhances the recovery and expansion of patient-derived GBM cells by combining Matrigel with an increased concentration of fetal bovine serum (FBS). This approach significantly improves cell attachment and recovery after thawing cells that have been cryopreserved for more than a decade. Importantly, the recovered cells retain key phenotypic characteristics and remain suitable for downstream applications, including drug testing and spheroid formation. Together, this optimized protocol provides a novel strategy to increase the availability of patient-derived GBM cells by improving their efficient recovery from long-term cryopreservation, thereby maximizing their utility in GBM research.
Key features
• Optimized for recovery of low-viability adherent cells, including long-term cryopreserved patient-derived GBM.
• Combined use of Matrigel coating and elevated FBS to enhance post-thaw attachment and recovery.
• Recovered cells maintain their morphology, marker expression, and functionality.
• Simple, effective protocol applicable to GBM and potentially to other adherent cell types.
Keywords: Adherent cell recovery (贴壁细胞复苏)Graphical overview
Overview of the optimized recovery protocol for patient-derived glioblastoma (GBM) cells after long-term cryopreservation
Background
Glioblastoma (GBM) is the most common and lethal primary brain tumor, characterized by aggressive growth and profound therapeutic resistance driven by intrinsic factors such as cellular heterogeneity and extrinsic barriers, including the blood–brain barrier [1]. Despite extensive research efforts, patient outcomes remain poor, highlighting the continued need for robust experimental models that accurately reflect patient tumor biology. Patient-derived GBM cells are therefore invaluable research tools, as they preserve key genetic, phenotypic, and functional characteristics of the original tumors and offer high translational relevance [2]. Consequently, the successful isolation, preservation, and recovery of these samples are critical for advancing GBM research.
Cryopreservation in liquid nitrogen (LN2) is the standard approach for long-term storage of biological materials, including patient-derived cells [3]. Conventional post-thaw recovery protocols typically involve rapid thawing in a 37 °C water bath, followed by seeding cells into standard culture medium supplemented with approximately 10% fetal bovine serum (FBS) and incubation until cell attachment and proliferation are observed [4,5]. While effective for many established cell lines, this approach often proves inadequate for fragile primary cells, particularly when initial cell numbers are low, cellular integrity at freezing is compromised, storage conditions fluctuate, or samples have been cryopreserved for extended periods [6]. In the case of patient-derived GBM cells stored for long durations, recovery failure can lead to irreversible loss of rare and irreplaceable patient material, as well as wasted resources associated with long-term biobanking. In our experience, GBM cells cryopreserved for more than a decade could not be successfully recovered or expanded using standard post-thaw protocols. These limitations underscore the need for an optimized recovery strategy specifically tailored to low-viability, adherent primary tumor cells.
Here, we describe an optimized post-thaw recovery protocol for patient-derived GBM cells that combines extracellular matrix support via Matrigel-coated culture surfaces with increased serum supplementation during the initial recovery phase. Matrigel has been shown to enhance cell adhesion and survival in fragile or low-adherent cell types, such as induced pluripotent stem cells (iPSCs), and may similarly support stressed GBM cells following long-term cryopreservation [7]. In parallel, elevating FBS concentration provides additional growth factors and survival cues to help cells overcome post-thaw stress and resume proliferation [8]. This protocol enables reliable recovery, expansion, and downstream use of patient-derived GBM cells following long-term cryopreservation and may be broadly applicable to other challenging primary adherent cell types.
Materials and reagents
Biological materials
1. Patient-derived glioblastoma cells (originally collected, isolated, and cryopreserved over a decade ago by a previous researcher [9]; subsequently thawed and utilized in our recently published study [10] and this protocol development); see Supplementary Materials of [10] for patient data details
Reagents
1. Dulbecco’s modified Eagle medium (DMEM), high glucose (Thermo Fisher Scientific, Gibco, catalog number: 12100046)
2. Fetal bovine serum (FBS) (Sigma-Aldrich, catalog number: F7524)
3. Penicillin-streptomycin mixture (double antibiotics, 100×) (Servicebio, catalog number: G4003)
4. Trypsin-EDTA (0.25%) (Thermo Fisher Scientific, Gibco, catalog number: 25200072)
5. Matrigel® basement membrane matrix, LDEV-free, 10 mL (Corning, catalog number: 354234)
6. Sodium chloride (NaCl) (Sigma-Aldrich, catalog number: S5886)
7. Sodium phosphate dibasic (Na2HPO4) (Sigma-Aldrich, catalog number: 106586)
8. Potassium phosphate monobasic (KH2PO4) (Sigma-Aldrich, catalog number: P0662)
9. APC anti-human CD44 antibody, dilution 1:100 (BioLegend, catalog number: 38806)
10. PE/Cyanine7 anti-human CD133 antibody, dilution 1:100 (BioLegend, catalog number: 393909)
11. Anti-nestin antibody, dilution 1:250 (Sigma-Aldrich, catalog number: MAB5326)
12. Anti-SOX2 antibody, dilution 1:250 (Sigma-Aldrich, catalog number: AB5603)
Solutions
1. Matrigel coating solution (see Recipes)
2. Optimized recovery medium (see Recipes)
3. Standard culture medium (see Recipes)
4. 1× phosphate-buffered saline (PBS) (see Recipes)
5. Trypsin solution 0.05% (see Recipes)
Recipes
1. Matrigel coating solution
| Reagent | Final concentration | Volume (for 6 mL)* |
| Matrigel | 0.3 mg/mL | 0.2 mL |
| Basal DMEM (high glucose) | n/a | 5.8 mL |
*This recipe provides an example for a Matrigel stock concentration of 9.0 mg/mL. The volume of basal DMEM (high glucose) added to the Matrigel aliquot was adjusted according to the lot-specific concentration reported in the manufacturer’s certificate of analysis for each Matrigel lot. To ensure a standardized final concentration of 0.3 mg/mL, the required dilution volume was calculated for each lot using the following formula:
Vmedium = [(Cstock × Valiquot)/0.3 mg/mL] - Valiquot
Vmedium is the required dilution volume of basal DMEM (high glucose) medium;
Cstock is the lot-specific concentration of the Matrigel stock (such as 9.0 mg/mL);
Valiquot is the volume of the frozen Matrigel aliquot (such as 0.2 mL);
Example calculation in this recipe:
Vmedium = [(9 × 0.2)/0.3] - 0.2 = 5.8 mL
Matrigel basement membrane matrix stock was stored at -80 °C until use or aliquoting. Aliquot volumes were prepared according to the manufacturer’s recommended working concentration range for coating (0.2–0.3 mg/mL); in our laboratory, a concentration of 0.3 mg/mL in 6 mL was routinely used as the working solution. For aliquoting, the Matrigel stock was thawed on ice and dispensed into pre-chilled 15 mL centrifuge tubes, which were then stored at -20 °C until use. To prepare the Matrigel coating solution, an aliquot was diluted with ice-cold DMEM (high glucose) to prevent gel formation upon warming. To ensure homogeneity, the diluted solution was incubated overnight at 4 °C. Although fresh preparation was preferred, working solutions were stored at 4 °C for no longer than one week.
2. Optimized recovery medium
| Reagent | Final concentration | Volume (for 50 mL) |
| Basal DMEM (high glucose) | 80% | 40 mL |
| FBS | 20% | 10 mL |
Fresh preparation is preferred, but if stored, the medium should be kept at 4 °C for no longer than one week to minimize the risk of contamination and degradation of nutrients. Warm the medium at 37 °C before use.
3. Standard culture medium
| Reagent | Final concentration | Volume (for 50 mL) |
| Basal DMEM (high glucose) | 79% | 44.5 mL |
| FBS | 10% | 5 mL |
| Penicillin-streptomycin mixture | 1× | 0.5 mL |
The medium should be kept at 4 °C for no longer than 2–4 weeks to minimize the risk of contamination and degradation of nutrients. Warm the medium at 37 °C before use.
4. 1× PBS
| Reagent | Final concentration | Amount (for 1,000 mL) |
| NaCl | 131.0 mM | 7.65 g |
| Na2HPO4 | 7.0 mM | 0.994 g |
| KH2PO4 | 3.0 mM | 0.408 g |
| Milli-Q water | n/a | 1,000 mL |
In our laboratory, 1,000 mL of 1× PBS was prepared by dissolving the chemical powders listed in the recipe in Milli-Q water. The solution was stirred until fully dissolved, and the pH was adjusted to approximately 7.4. The buffer was then brought to a final volume of 1,000 mL and sterilized by autoclaving. After sterilization, the solution was allowed to cool overnight before use. Sterile PBS was stored at room temperature for up to 6 months. Sterile 1× PBS from commercial sources can be used when preparation is not preferred.
5. Trypsin solution (0.05%)
| Reagent | Final concentration | Volume (for 50 mL) |
| 0.25% trypsin | 0.05% | 10 mL |
| 1× PBS | n/a | 40 mL |
Store 0.05% trypsin solution at 4 °C for no longer than 1–2 weeks for reliable enzyme activity. Warm at room temperature before use.
Laboratory supplies
1. 6-well clear TC-treated multiple well plates, individually wrapped, sterile (Corning, catalog number: 3516)
2. 25 cm2 rectangular canted neck cell culture flask with vent cap (Corning, catalog number: 430639)
3. 75 cm2 U-shaped canted neck cell culture flask with vent cap (Corning, catalog number: 431464U)
4. Centrifuge tubes with flat cap, 15 mL, sterilized (JET Biofil, catalog number: CFT011150)
5. Centrifuge tubes with flat cap, 50 mL, sterilized (JET Biofil, catalog number: CFT011500)
6. 2 mL internal threaded polypropylene cryogenic vial, self-standing with round bottom (Corning, catalog number: 430488)
7. 10 μL pipette tips, non-filtered, clear (Corning, Axygen®, catalog number: T-300)
8. 1–200 μL pipette tips, graduated, yellow (Corning, catalog number: 4112)
9. 1,000 μL pipette tips (maximum working volume 1,250 μL), graduated, natural (Corning, catalog number: 4114)
Equipment
1. CO2 incubator (Thermo Scientific, FormaTM Steri-CycleTM Incubator, 184 L, Polished Stainless Steel, model: 371)
2. Class II biological safety cabinet (Thermo Fisher Scientific, model: MSC-Advantage BSC 1.8)
3. Inverted microscope (Nikon, model: Eclipse TS100)
4. Water bath at 37 °C (Julabo, model: SW23)
5. Pipetman P1000, 100–1,000 μL (Gilson)
6. Motorized pipette controller (Corning, model: StripettorTM Ultra Pipet Controller 4099)
7. Disposable serological pipette 5, 10, and 25 mL (Wuxi NEST Biotechnology)
8. Laboratory/medical refrigerator at 37 °C (Panasonic, model: MPR-1411)
9. Liquid nitrogen tank (Thermo Fisher Scientific, model: CY509109)
Procedure
登录/注册后免费查看全文
文章信息
稿件历史记录
提交日期: Jan 8, 2026
接收日期: Mar 13, 2026
在线发布日期: Mar 23, 2026
出版日期: Apr 5, 2026
版权信息
© 2026 The Author(s); This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/).
如何引用
Khotchawan, W., Lorthongpanich, C., Kheolamai, P., Sathornsumetee, S. and Issaragrisil, S. (2026). Recovery and Expansion of Patient-Derived Glioblastoma Cells After Long-term Cryopreservation. Bio-protocol 16(7): e5661. DOI: 10.21769/BioProtoc.5661.
分类
癌症生物学 > 通用技术 > 细胞生物学试验 > 细胞活性
细胞生物学 > 细胞分离和培养 > 细胞生长
您对这篇实验方案有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
Share
Bluesky
X
Copy link


